Trial reportLeukemia2020
Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study.
Open access · hybridAbstract readClinical Trial, Phase IClinical Trial, Phase IILetter
In one paragraph
Trial report in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 41 citations in OpenAlex.
- Thorough QT Study on the Effect of Therapeutic and Supratherapeutic Dosing of Givinostat in Healthy Volunteers.Clinical pharmacology in drug development · 2026Trial
- Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program.Blood cancer journal · 2021Trial
- HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives.RSC advances · 2026Review
- Advances in polycythemia vera treatment with targeted therapies and clinical trials.Discover oncology · 2025Review
- Polycythaemia vera.Nature reviews. Disease primers · 2025Review
- DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications.Current issues in molecular biology · 2025Review
- Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024Review
- Givinostat: First Approval.Drugs · 2024Review
- SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera.Clinical lymphoma, myeloma & leukemia · 2024Review
- In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients.CPT: pharmacometrics & systems pharmacology · 2024Article
- Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.Signal transduction and targeted therapy · 2023Review
- Givinostat for Becker muscular dystrophy: A randomized, placebo-controlled, double-blind study.Frontiers in neurology · 2023Article
- Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia.Biomedicines · 2022Review
- Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia.Current hematologic malignancy reports · 2022Review
- Differentiation of crescent-forming kidney progenitor cells into podocytes attenuates severe glomerulonephritis in mice.Science translational medicine · 2022Article
- Treatment options and pregnancy management for patients with PV and ET.International journal of hematology · 2022Review
- HDAC Inhibition as Potential Therapeutic Strategy to Restore the Deregulated Immune Response in Severe COVID-19.Frontiers in immunology · 2022Article
- Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.Current hematologic malignancy reports · 2021Review
- Emerging agents and regimens for polycythemia vera and essential thrombocythemia.Biomarker research · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 17 institutions in 5 countries.
Alessandro RambaldiDepartment of Oncology and Hematology, University of Milan and ASST Papa Giovanni XXIII, Bergamo, Italy. alessandro.rambaldi@unimi.it.ORCID http://orcid.org/0000-0002-3739-7502
Alessandra IurloHematology Division, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID http://orcid.org/0000-0002-4401-0812
Alessandro M VannucchiDepartment of Experimental and Clinical Medicine, University of Florence, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy.
Richard NobleDepartment of Hematology, Royal Cornwall Hospital, Truro, UK.
Nikolas von BubnoffDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Attilio GuariniHematology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Bruno MartinoOncology-Hematology Department, A.O. "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
Antonio PezzuttoDepartment of Hematology Oncology, Charité' Medical School, Campus Benjamin Franklin, Berlin, Germany.ORCID http://orcid.org/0000-0002-3246-4470
Giuseppe CarliU.O. Hematology, San Bortolo Hospital, Vicenza, Italy.
Marianna De MuroHematology and Stem Cells Transplantation Unit, Campus Bio-Medico, University Hospital, Rome, Italy.
Stefania LucianiU.O. Clinical Hematology, Presidio Ospedaliero "Spirito Santo"-A.S.L. Azienda Sanitaria Locale, Pescara, Italy.
Mary Frances McMullinCentre for Medical Education, Queen's University Belfast, Belfast, UK.ORCID http://orcid.org/0000-0002-0773-0204
Nathalie CambierService d'Oncologie Hématologie, Hospital Saint Vincent de Paul-GHICL Lille, Lille, France.
Jean-Pierre MarolleauService d'Oncologie Hématologie Clinique, CHU Amiens-Hospital Sud, Amiens, France.
Ruben A MesaMayo Clinic Cancer Center, Scottsdale, AZ, USA.
Raoul TibesNew York University School of Medicine & Perlmutter Cancer Center/ NYU Langone Health, New York, NY, USA.
Alessandro PancrazziDepartment of Experimental and Clinical Medicine, University of Florence, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy.
Francesca GesulloDepartment of Experimental and Clinical Medicine, University of Florence, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy.
Paolo BetticaClinical R&D Department, Italfarmaco S.p.A., Cinisello Balsamo, Italy.
Sara ManzoniClinical R&D Department, Italfarmaco S.p.A., Cinisello Balsamo, Italy.
Silvia Di TolloClinical R&D Department, Italfarmaco S.p.A., Cinisello Balsamo, Italy.
Azienda Ospedaliero-Universitaria Careggi · ITItalfarmaco (Italy) · ITASL Roma · ITAzienda ospedaliera "Bianchi-Melacrino-Morelli" · ITCentre Hospitalier Universitaire Amiens-Picardie · FRCharité - Universitätsmedizin Berlin · DEFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITGroupe Hospitalier de l'Institut Catholique de Lille · FRIstituto Tumori Bari · ITMayo Clinic in Arizona · USNYU Langone Health · USOspedale San Bortolo · ITQueen's University Belfast · GBRoyal Cornwall Hospital · GBUniversità Campus Bio-Medico · ITUniversity of Freiburg · DEUniversity of Milan · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overCarbamatesFemaleHumansJanus Kinase 2MaleMaximum Tolerated DoseMiddle AgedMutationPolycythemia VeraQuality of LifeCarbamatesgivinostatJAK2 protein, humanJanus Kinase 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.